Search research articles
Contact Us
Filters
Showing results (1-10 of 22) with videos related to
Page
of 3
Sort By:
Annals of the New York Academy of Sciences
|
July 15, 2004
Postnatal development of prefrontal inhibitory circuits and the pathophysiology of cognitive dysfunction in schizophrenia
David A Lewis, Dianne Cruz, Stephen Eggan, et al.
Journal of Hematology & Oncology
|
August 9, 2018
Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
Moshe Talpaz, Susan Erickson-Viitanen, Kevin Hou, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 10, 2002
P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease
E Scott Priestley, Indawati De Lucca, Bahman Ghavimi, et al.
American Journal of Ophthalmology
|
December 8, 2019
Perspective on Systematic Medical Literature Reviews and Meta-Analyses
Jay S Pepose, Gary N Foulks, J Daniel Nelson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 24, 2025
Basic Science and Pathogenesis
Josh Krivinko, Susan Erickson, Akayla Lewin, et al.
Leukemia Research
|
May 21, 2013
Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study
Ruben A Mesa, Alan Shields, Thomas Hare, et al.
Clinical Lung Cancer
|
April 24, 2018
A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation
Giuseppe Giaccone, Rachel E Sanborn, Saiama N Waqar, et al.
Antiviral Chemistry & Chemotherapy
|
June 7, 2003
HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset)
Romas Geleziunas, Karen Gallagher, Hangchun Zhang, et al.
Antiviral Chemistry & Chemotherapy
|
June 7, 2003
Cellular pharmacology of D-d4FC, a nucleoside analogue active against drug-resistant HIV
Susan Erickson-Viitanen, Jing-Tao Wu, Guoen Shi, et al.
Cancer
|
April 12, 2011
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial
Ruben A Mesa, Hagop Kantarjian, Ayalew Tefferi, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 22) with videos related to
Sort By:
Page
of 3
Annals of the New York Academy of Sciences
|
July 15, 2004
Postnatal development of prefrontal inhibitory circuits and the pathophysiology of cognitive dysfunction in schizophrenia
David A Lewis, Dianne Cruz, Stephen Eggan, et al.
Journal of Hematology & Oncology
|
August 9, 2018
Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
Moshe Talpaz, Susan Erickson-Viitanen, Kevin Hou, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 10, 2002
P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease
E Scott Priestley, Indawati De Lucca, Bahman Ghavimi, et al.
American Journal of Ophthalmology
|
December 8, 2019
Perspective on Systematic Medical Literature Reviews and Meta-Analyses
Jay S Pepose, Gary N Foulks, J Daniel Nelson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 24, 2025
Basic Science and Pathogenesis
Josh Krivinko, Susan Erickson, Akayla Lewin, et al.
Leukemia Research
|
May 21, 2013
Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study
Ruben A Mesa, Alan Shields, Thomas Hare, et al.
Clinical Lung Cancer
|
April 24, 2018
A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation
Giuseppe Giaccone, Rachel E Sanborn, Saiama N Waqar, et al.
Antiviral Chemistry & Chemotherapy
|
June 7, 2003
HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset)
Romas Geleziunas, Karen Gallagher, Hangchun Zhang, et al.
Antiviral Chemistry & Chemotherapy
|
June 7, 2003
Cellular pharmacology of D-d4FC, a nucleoside analogue active against drug-resistant HIV
Susan Erickson-Viitanen, Jing-Tao Wu, Guoen Shi, et al.
Cancer
|
April 12, 2011
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial
Ruben A Mesa, Hagop Kantarjian, Ayalew Tefferi, et al.
Page
of 3